Certain Clidinium Bromide and Products Containing Same; Commission Decision Not To Review an Initial Determination Granting Complainants' Unopposed Motion To Terminate the Investigation Based on the Withdrawal of the Amended Complaint; Termination of the Investigation, 37514 [2018-16484]

Download as PDF 37514 Federal Register / Vol. 83, No. 148 / Wednesday, August 1, 2018 / Notices INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1109] Certain Clidinium Bromide and Products Containing Same; Commission Decision Not To Review an Initial Determination Granting Complainants’ Unopposed Motion To Terminate the Investigation Based on the Withdrawal of the Amended Complaint; Termination of the Investigation U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (‘‘ID’’) (Order No. 12) of the presiding Administrative Law Judge (‘‘ALJ’’) granting Complainants’ unopposed motion to terminate the investigation in its entirety based on the withdrawal of the amended complaint. The investigation is terminated. FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 708–4716. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at https:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on April 23, 2018, based on a complaint filed by Valeant Pharmaceuticals North America LLC of Bridgewater, New Jersey and Valeant Pharmaceuticals International, Inc. of Laval, Canada (collectively, ‘‘Valeant’’). See 83 FR 17676–7 (Apr. 23, 2018). The complaint, as amended, alleges violations of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), based upon the importation into the United States, the sale for importation, and the sale sradovich on DSK3GMQ082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 20:07 Jul 31, 2018 Jkt 244001 within the United States after importation of certain clidinium bromide and products containing same by reason of unfair acts or methods of competition, the threat or effect of which is to destroy or substantially injure an industry in the United States. See id. The notice of investigation named as respondents in this investigation: Bi-Coastal Pharma International LLC and Bi-Coastal Pharmaceutical Corporation (collectively, ‘‘Bi-Coastal’’) of Shrewsbury, New Jersey; ECI Pharmaceuticals LLC of Fort Lauderdale, Florida; Virtus Pharmaceuticals LLC of Tampa, Florida; and Virtus Pharmaceuticals OPCO II LLC of Nashville, Tennessee. See id. The Office of Unfair Import Investigations is also a party to this investigation. See id. On June 12, 2018, the ALJ partially terminated the investigation as to Bi-Coastal based on a settlement agreement. See Order No. 9 (June 12, 2018), unreviewed, Comm’n Notice (June 28, 2018). On July 9, 2018, Valeant filed an unopposed motion (Motion) to terminate the investigation in its entirety based on the withdrawal of the amended complaint. On July 10, 2018, the ALJ issued the subject ID (Order No. 12) granting the Motion. In accordance with Commission Rule 210.21(a)(1), 19 CFR 210.21(a)(1), the ID notes that ‘‘[t]here are no agreements, written or oral, express or implied between Complainants and Respondents concerning the subject matter of this Investigation.’’ See ID at 1 (citing Motion at 2). In addition, the ID finds that ‘‘there are no extraordinary circumstances that warrant denying the motion.’’ See id. No petition for review of the ID was filed. The Commission has determined not to review the ID. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: July 27, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–16484 Filed 7–31–18; 8:45 am] BILLING CODE 7020–02–P PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1126] Certain Water Filters and Components Thereof Institution of Investigation U.S. International Trade Commission ACTION: Notice AGENCY: Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on June 8, 2018, under section 337 of the Tariff Act of 1930, as amended, on behalf of Electrolux Home Products, Inc. of Charlotte, North Carolina and KX Technologies, LLC of West Haven, Connecticut. An amended complaint was filed on June 28, 2018. A letter supplementing the amended complaint was filed on July 10, 2018. The amended complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain water filters and components thereof by reason of infringement of U.S. Patent No. 8,673,146 (‘‘the ’146 patent’’); U.S. Patent No. 8,137,551 (‘‘the ’551 patent’’); U.S. Patent No. 9,233,322 (‘‘the ’322 patent’’); and U.S. Patent No. 9,901,852 (‘‘the ’852 patent’’). The amended complaint further alleges that an industry in the United States exists as required by the applicable Federal Statute. The complainants request that the Commission institute an investigation and, after the investigation, issue a general exclusion order or, in the alternative, a limited exclusion order, and cease and desist orders. ADDRESSES: The amended complaint, except for any confidential information contained therein, is available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW, Room 112, Washington, DC 20436, telephone (202) 205–2000. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205–2000. General information concerning the Commission may also be obtained by accessing its internet server at https:// www.usitc.gov. The public record for SUMMARY: E:\FR\FM\01AUN1.SGM 01AUN1

Agencies

[Federal Register Volume 83, Number 148 (Wednesday, August 1, 2018)]
[Notices]
[Page 37514]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-16484]



[[Page 37514]]

=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1109]


Certain Clidinium Bromide and Products Containing Same; 
Commission Decision Not To Review an Initial Determination Granting 
Complainants' Unopposed Motion To Terminate the Investigation Based on 
the Withdrawal of the Amended Complaint; Termination of the 
Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review an initial determination 
(``ID'') (Order No. 12) of the presiding Administrative Law Judge 
(``ALJ'') granting Complainants' unopposed motion to terminate the 
investigation in its entirety based on the withdrawal of the amended 
complaint. The investigation is terminated.

FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General 
Counsel, U.S. International Trade Commission, 500 E Street SW, 
Washington, DC 20436, telephone (202) 708-4716. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW, Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its internet server at https://www.usitc.gov. The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on April 23, 2018, based on a complaint filed by Valeant 
Pharmaceuticals North America LLC of Bridgewater, New Jersey and 
Valeant Pharmaceuticals International, Inc. of Laval, Canada 
(collectively, ``Valeant''). See 83 FR 17676-7 (Apr. 23, 2018). The 
complaint, as amended, alleges violations of section 337 of the Tariff 
Act of 1930, as amended (19 U.S.C. 1337), based upon the importation 
into the United States, the sale for importation, and the sale within 
the United States after importation of certain clidinium bromide and 
products containing same by reason of unfair acts or methods of 
competition, the threat or effect of which is to destroy or 
substantially injure an industry in the United States. See id. The 
notice of investigation named as respondents in this investigation: Bi-
Coastal Pharma International LLC and Bi-Coastal Pharmaceutical 
Corporation (collectively, ``Bi-Coastal'') of Shrewsbury, New Jersey; 
ECI Pharmaceuticals LLC of Fort Lauderdale, Florida; Virtus 
Pharmaceuticals LLC of Tampa, Florida; and Virtus Pharmaceuticals OPCO 
II LLC of Nashville, Tennessee. See id. The Office of Unfair Import 
Investigations is also a party to this investigation. See id. On June 
12, 2018, the ALJ partially terminated the investigation as to Bi-
Coastal based on a settlement agreement. See Order No. 9 (June 12, 
2018), unreviewed, Comm'n Notice (June 28, 2018).
    On July 9, 2018, Valeant filed an unopposed motion (Motion) to 
terminate the investigation in its entirety based on the withdrawal of 
the amended complaint. On July 10, 2018, the ALJ issued the subject ID 
(Order No. 12) granting the Motion. In accordance with Commission Rule 
210.21(a)(1), 19 CFR 210.21(a)(1), the ID notes that ``[t]here are no 
agreements, written or oral, express or implied between Complainants 
and Respondents concerning the subject matter of this Investigation.'' 
See ID at 1 (citing Motion at 2). In addition, the ID finds that 
``there are no extraordinary circumstances that warrant denying the 
motion.'' See id.
    No petition for review of the ID was filed. The Commission has 
determined not to review the ID.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: July 27, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018-16484 Filed 7-31-18; 8:45 am]
 BILLING CODE 7020-02-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.